RATIONALE: Patients commonly seek medical attention for chronic cough; however, the etiology is often difficult to identify. The purpose of this survey was to characterize primary care patients with chronic cough (cough lasting >8 weeks), identify possible causes, and determine the impact of chronic cough. METHODS: A survey of 13 questions regarding chronic cough was mailed to a random sample of 270 primary care providers in the San Diego, CA area. RESULTS: In all, 42 surveys were returned. Respondents estimated that of patients seeking treatment for chronic cough, 53% were female, 32% were aged 30-50 years, and 55% were aged >50 years. Respondents indicated that the majority of the cough had been present for 2-6 months (n518 respondents), 6-12 months (n510), or more than 1 year (n51) and the primary cause was gastroesophageal reflux (n523), rhinosinusitis (n521), asthma (n59), ''other'' (n55), COPD (n54), or idiopathic (n52). The majority of respondents indicated they referred their patients with chronic cough to pulmonologists (n533) and allergists (n526). Respondents indicated that their patients with chronic cough typically experienced decreased quality of life (n535), loss of sleep (n531), embarrassment (n527), absence from work/school (n514), and depression (n54). CONCLUSIONS: Chronic cough in the primary care setting is generally in patients of either gender who are over the age of 50 and appears to be primarily caused by gastroesophageal reflux or rhinosinusitis. Primary care providers typically refer patients with chronic cough to pulmonologists and allergists. Chronic cough negatively affects patients' quality of life and sleep, and is a source of embarrassment.
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Every Breath You Take -Improving Asthma Wellness Aparna S. Daley; PennState College of Medicine Hershey Medical Center, Wyomissing, PA. RATIONALE: Good control of asthma reduces related deaths and costs. The CDC recommends pneumococcal vaccination for patients with asthma, aged 18-64 years. Guidelines recommend assessment and documentation of asthma severity at each clinic visit. Objectives were to determine whether specific interventions would improve rates of pneumococcal vaccination and asthma severity documentation in asthma patients. METHODS: IRB exempt. Electronic records were used to identify patients above the age of 18 years with a diagnosis of asthma seen at the Family Health Center Clinic during a period designated as ''2017''. Interventions implemented included individualized EMR alerts placed on patient charts; verbal reminders to residents during weekly pre-visit team huddles; pocket cards provided to residents; asthma severity forms and two educational sessions. An analysis of pneumococcal vaccination and asthma severity documentation was performed after the implementation of interventions during a period designated as ''2018''. RESULTS: 52 patients were identified in the 2017 period and data was compared to the 2018 period. Prior to the interventions, 24 patients had received the pneumococcal vaccination (46%). Analysis of data was performed using one-tailed non-parametric tests. Results revealed that after the intervention, 29 patients had received the pneumococcal vaccination (56%, p 5 0.032). Prior to the intervention, 23 patients had documentation of asthma severity (44%). After the intervention, 35 patients had documentation of asthma severity (67%, p < 0.0001). CONCLUSIONS: Our results suggest that optimal resident education, EMR alerts and pre-visit team huddles were effective at improving the rates of documentation of asthma severity and increasing the rates of pneumococcal vaccination.
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Montelukast does not increase the risk of neuropsychiatric disease in children with asthma: a nationwide population-based cohort study (n514668) and a nonMontelukast cohort (n58489) were conducted and matched using propensity score. We compared the incidence of hazard ratios of subsequent neuropsychiatric diseases. The maximal follow-up time was 9 years. RESULTS: The incidence of overall neuropsychiatric (NP) disorder in Montelukast cohort was not significantly higher than that in nonMontelukast cohort (adjusted hazard ratio (aHR)5 0.91, 95% confidence interval50.81-1.01). Boys in Montelukast cohort had lower risk NP disease (aHR50.83, 95% CI50.698-0.977). Compared with nonMontelukast cohort, children took Montelukast for less than 101 days had lower risk for NP disease (aHR5 0.62, 95% CI50.40-0.96). In both Montelukast and non-Montelukast cohort, the risks for NP disease increased in those with not well-controlled asthma (aHR530.92, 95% CI 5 12.79-74.76 and aHR521.09, 95% CI 5 6.77-65.70, respectively). CONCLUSIONS: Our population-based cohort study showed that the risk of neuropsychiatric disease in asthmatic children is not elevated by Montelukast usage whereas increased in those without adequate control. . Similarly, asthma was associated with higher odds of osteoporosis (P<0.0001 for all), osteopenia (P<0.0001 for all) and ankylosing spondylitis (P< _0.02 for all) in all 7 years, and osteomalacia in 6 of 7 years (P<0.02 for [2007] [2008] [2009] [2010] [2011] [2012] . There was significant sex-and age-related differences of the associations of asthma with these comorbidities. CONCLUSIONS: Asthma was associated with osteopenia, osteoporosis, osteomalacia, ankylosing spondylitis and pathologic fractures.
